The administration of luteal phase low molecular weight heparin to improve live births after recurrent implantation failure: A prospective randomized clinical trial
Heparin has been shown to play a regulatory role in the process of endometrial receptivity and implantation independently from its antithrombin effect. A role for low molecular weight heparin (LMWH) in improving the reproductive outcome of women with recurrent implantation failure (RIF) has been proposed on the basis of low-quality evidence.
The primary aim of this study was to address the existing knowledge gap by investigating whether the administration of LMWH in the luteal phase increases IVF/ICSI outcomes in RIF women.Read More